Plus: The ongoing financial struggles of rural hospitals, a major measles outbreak and the FDA approves treatment for a rare ...

The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to ...

Novartis has brought abelacimab back into the fold. Six years after spinning the asset out to form Anthos Therapeutics, ...

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market for deals to fill its drug pipeline and power sales growth into the 2030s, ...

CEO Vas Narasimhan told the Wall Street Journal the company is searching for next-generation obesity drug candidates, even if ...

The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...

( MENAFN - Swissinfo) Swiss Pharmaceutical heavyweight Novartis said profit will rise this year as new medicines help offset competition from copycats of its best-selling drug. Core operating profit ...

The pharma major beat analysts’ expectations in the fourth quarter of 2024, despite looming competition for its top heart ...

During 2024, the radiopharmaceutical Pluvicto achieved blockbuster status, while sales of the breast cancer drug Kisqali grew 46 percent compared to 2023.

CEO Vas Narasimhan highlighted Novartis' strong performance in Q4 2024, with sales increasing 16% and core operating income rising 29% in constant currency. For the full year, the company achieved a ...

One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...